SciELO - Scientific Electronic Library Online

 
vol.12 issue4Delayed postoperative radiation therapy in local control of squamous cell carcinoma of the tongue and floor of the mouthFrom one side to the other: what is essential? Perception of oncology patients and their caregivers in the beginning of oncology treatment and in palliative care author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Einstein (São Paulo)

Print version ISSN 1679-4508On-line version ISSN 2317-6385

Einstein (São Paulo) vol.12 no.4 São Paulo Oct./Dec. 2014  Epub Dec 16, 2014

http://dx.doi.org/10.1590/S1679-45082014RC3110 

Original Article

Oxidative stress and plasma lipoproteins in cancer patients

Fernanda Maria Machado Maia 1  

Emanuelly Barbosa Santos 1  

Germana Elias Reis 1  

1Universidade Estadual do Ceará, Fortaleza, CE, Brazil.

ABSTRACT

Objective

To evaluate the relation between oxidative stress and lipid profile in patients with different types of cancer.

Methods

This was an observational cross-sectional. A total of 58 subjects were evaluated, 33 males, divided into two groups of 29 patients each: Group 1, patients with cancer of the digestive tract and accessory organs; Group 2 patients with other types of cancers, all admitted to a public hospital. The plasma levels (lipoproteins and total cholesterol, HDL, and triglycerides, for example) were analyzed by enzymatic kits, and oxidative stress based on thiobarbituric acid-reactive substances, by assessing the formation of malondialdehyde.

Results

In general the levels of malondialdehyde of patients were high (5.00μM) as compared to 3.31μM for healthy individuals. The median values of lipids exhibited normal triacylglycerol (138.78±89.88mg/dL), desirable total cholesterol values (163.04±172.38mg/dL), borderline high LDL (151.30±178.25mg/dL) and low HDL (31.70±22.74mg/dL). Median HDL levels in Group 1 were lower (31.32mg/dL) than the cancer patients in Group 2 (43.67mg/dL) (p=0.038). Group 1 also showed higher levels of oxidative stress (p=0.027).

Conclusion

The lipid profile of patients with cancer was not favorable, which seems to have contributed to higher lipid peroxidation rate, generating a significant oxidative stress.

Key words: Chronic disease; Neoplasms; Lipoproteins; Lipids; Oxidative stress

INTRODUCTION

Cancer is the name given to a set of over one hundred diseases with a common feature: disorderly growth of cells that invade tissues and organs. It is regarded as a public health problem in Brazil. National estimates for 2014 point to 76 thousand new cases of cancer, including non-melanoma skin cancer.(1) There are many causes, which could be external (environment and habits) or pertaining to the inner body (genetically determined), and interrelated.(2)

Among the mechanisms related to the pathogenesis of non-communicable chronic diseases, including cancer, we have changes caused by oxidative metabolism.(3) The generation of free radicals is a continuous and physiological cell process.(4) In adequate proportions, its production will enable the generation of energy through adenosine triphosphate (ATP), phagocytosis, cell growth regulation and the participation in defense mechanisms during the infectious process. However, their excessive production shows harmful effects.(5)

Nonetheless, an imbalance between reactive species concentrations and antioxidant defense mechanisms in the body, favoring the first, will result in oxidative stress. The harmful effects of this process are membrane lipid peroxidation and damage caused to tissue and membrane proteins, to enzymes, to carbohydrates, in addition to oxidative damage to deoxyribonucleic acid (DNA).(6,7)

The metabolism of cancer patients changes gradually, affecting all metabolic pathways. As for carbohydrate metabolism, tumors show an excessive glucose consumption, causing glucose intolerance, with peripheral insulin resistance.(8,9) Protein catabolism is present, while most of the times there is a massive loss of musculoskeletal tissue in those patients. This event is related to a sulfated glycoprotein called proteolysis-inducing factor (PIF). This entire scenario contributes to the cachectic state very often encountered in cancer patients.(10) As for lipid metabolism, inhibition of plasma lipoprotein lipase activity leads to hyperlipidemia.(11) Increase of lipolysis associated with lowered lipogenesis; and increased turnover of glycerol, free fatty acids, and triacylglycerols (which are depleted from the adipose tissue) are all metabolic changes induced by advanced tumors, and they may be related to an increase of hormone-sensitive lipase (HSL) and to the release of lipolytic tumor factors.(11,12) Lipolytic activity can also be mediated by the lipid mobilization factor (LMF).(10)

OBJECTIVE

To assess the relation between oxidative stress and lipid profile in patients with different types of cancer.

METHODS

This was an observational, cross-sectional study involving cancer patients admitted to the Hospital Geral Dr. César Cals, in the city of Fortaleza (CE). This study has been reviewed and approved by the Ethics Committee of the abovementioned hospital (protocol 497/2011 and CAAE 0011.0.041.038-11). All research subjects participated voluntarily and signed the Informed Consent. The study was conducted from July 2011 to July 2012.

The inclusion criteria were patients with all types of cancer and aged over 18 years. The exclusion criterion was having other non-communicable chronic diseases. The convenience sample consisted of 58 patients.

After patients gave their consent to join the research, a 1mL sample of plasma was requested from the clinical laboratory at the abovementioned hospital in order to determine oxidative stress and plasma lipoprotein levels.

Lipid peroxidation (oxidative stress) was determined based on thiobarbituric acid reactive substances (TBARS),(13) with changes. The results were calculated according to a standard curve made from malondialdehyde (MDA) at 4µM. As an MDA reference value we considered that of healthy individuals, which is 3.31µM.(14)

Total cholesterol, triacylglycerol and high-density lipoprotein cholesterol (HDL-c) were determined through enzymatic methods, using commercial Labteste®reagents, while all tests were performed twice.

Total cholesterol, triacylglycerol and HDL-c levels were measured using 10:10:50µL, respectively, from the plasma sample, with 1mL of the respective work reagent for each lipoprotein. After 10 minutes in a heated bath at 37°C, we measured the sample absorbance and the absorbance of each standard at 500-510nm, using a digital Photonics® spectrophotometer. For HDL-c dosage, we first homogenized 250µL of plasma and 250µL of the reagent. They were centrifuged at 3,500 x g for 15 minutes and then the clear supernatant, with HDL-c, was pipetted for the assay. Low-density lipoprotein cholesterol (LDL-c) levels were obtained through the equation:(15)

LDL-c = total cholesteral – HDL-c – triacylglycerols/5, valid for triacylglycerols <400mg/dL

The results were classified following the National Cholesterol Education Program (NCEP) values, according to which total cholesterol levels <200mg/dL are desirable; levels ranging from 200 to 239mg/dL are borderline high; and levels ≥240mg/dL are high. For triacylglycerols, values are considered normal when <150mg/dL; borderline when ranging from 150 to 199mg/dL; high when ranging from 200 to 499mg/dL; and very high when ≥500mg/dL. For HDL cholesterol, levels were considered low when <40mg/dL; normal when ranging from 40 to 59mg/dL; and high if ≥60mg/dL. For LDL cholesterol, values described as optimal were <100mg/dL; borderline optimal when ranging from 100 to 129mg/dL; borderline high when ranging from 130 and 159mg/dL; high when ranging from 160 to 189mg/dL; and very high if >190mg/dL.(16)

Statistical analyses were performed using the software Statistical Package for Social Sciences (SPSS®), version 21. Through the Kolmogorov-Smirnov test we observed that continuous data had normal distribution. In order to analyze median differences in oxidative stress, total cholesterol, HDL-c, LDL-c and triacylglycerols, all 58 subjects in the sample were divided into two groups of 29 patients: Group 1, with cancer in the gastrointestinal tract and accessory organs, including stomach (13), pancreas (5), esophagus (3), colon (3), cecum (1), rectum (1), pharynx (1), intestine (1) bile ducts (1); Group 2, patients with other types of cancer, including hematologic (11), female genital organs (5), prostate (3), bladder (2), lung (2), thyroid (2), mediastine (2), placenta (1) and kidney (1) cancer. Medians were compared by the Student’s t test. Discrete variables obtained through counting were analyzed according to frequency dispersion by the χ2 test. When the amount of data available was lower than the minimum limit for χ2, we applied the Fisher’s exact test. Results were expressed as median±standard deviation, while p<0.05 was defined as statistically significant.

RESULTS

Among the patients we studied, there was a higher prevalence of stomach (22.4%), hematologic (19.0%), pancreatic and female genital organ (with 8.6% each) cancer, and of esophageal, colon and prostate cancer (with 5.1% each).

We also noticed a higher prevalence of gastric cancer in that sample, with predominance in the male sex (56.9%).

The oxidative stress median was 5.00μM, with 63.8% of individuals showing high oxidative stress levels. As for patients’ lipid profile, we observed the following factors: triacylglycerol median was normal (138.78±89.88mg/dL), total cholesterol was at desirable levels (163.04±172.38mg/dL), LDL-c was borderline high (151.30±178.25mg/dL) and HDL-c was low (31.70±22.74mg/dL) (Table 1).

However, 27.6% (16/58) of cancer patients exhibited total cholesterol values classified as borderline high or high; 58.6% (34/58) exhibited low HDL-c levels; and 29.3% (17/58) showed high triacylglycerol levels (Table 1).

Table 1 Distribution of cancer patients seen at Hospital Geral Dr. César Cals, from July 2011 to July 2012, according to the variables studied 

Variables Median (n=58) Group 1 n (%) Group 2 n (%) p value*
Malondialdehyde (μM) 5.00±4.07      
Normal 21 (36.2%) 9 (42.9) 12 (57.1) 0.412
High 37 (63.8%) 20 (54.1) 17 (45.9)  
Total cholesterol (mg/dL) 163.04±172.32      
Desirable 42 (72.4%) 21 (50.0) 21 (50.0) 0.865
Borderline high 5 (8.6%) 3 (60) 2 (40)  
High 11 (19.0%) 5 (45.5) 6 (54.5)  
HDL-c (mg/dL) 31.70±22.74      
Low 34 (58.6%) 22 (64.7) 12 (35.3) 0.019
Normal 14 (24.2%) 3 (21.4) 11 (78.6)  
High 10 (17.2%) 4 (40.0) 6 (60.0)  
Triacylglycerol (mg/dL) 138.78±89.88      
Normal 31 (53.5%) 17 (54.8) 14 (45.2) 0.688
Borderline 10 (17.2%) 4 (40.0) 6 (60.0)  
High 17 (29.3%) 8 (47.1) 9 (52.9)  
LDL-c (mg/dL) 151.30±178.25      
Optimal 12 (20.7%) 6 (50.0) 6 (50.0) 0.296
Borderline optimal 11 (19.0%) 3 (27.3) 8 (72.7)  
Borderline high to very high 35 (60.3%) 20 (57.1) 15 (42.9)  

* χ2 Test. Group 1 formed by individuals with gastrointestinal cancer; Group 2 formed by individuals with other types of cancer. HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol.

When comparing Group 1 (n=29), which had gastrointestinal and accessory organ cancer, with Group 2 (n=29), which included patients with other types of cancer, an association was observed between the higher prevalence of individuals in Group 1 with low HDL-c than in Group 2 (p=0.019) (Table 1).

With respect to differences in median HDL-c values, Group 1 had lower levels (31.32mg/dL) than cancer patients in Group 2 (43.67mg/dL) (p=0.038). Higher oxidative stress values were observed in Group 1 patients, with 6.83µM, while Group 2 had 4.46µM (p=0.027) (Table 2).

Table 2 Median malondialdehyde and lipoprotein values of cancer patients seen at Hospital Geral Dr. César Cals, from July 2011 to July 2012 

Biochemical parameters Group 1 Group 2 p value*
Malondialdehyde (μM) 6.83±4.92 4.46±2.57 0.027
Total cholesterol (mg/dL) 209.36±161.73 210.82±185.30 0.975
Triacylglycerol (mg/dL) 141.85±86.36 146.48±94.76 0.878
HDL-c (mg/dL) 31.32±21.18 43.67±22.92 0.038
LDL-c (mg/dL) 206.40±171.24 196.45±187.90 0.834

*Student’s t test. HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol.

DISCUSSION

This study had important limitations with respect to its population and sample. The defined population was limited to a single study location, and we did not choose a specific type of cancer, which could yield more accurate and applicable results for the general population. Another important limitation is the sample size, since we did not calculate a representative sample and cannot make generalizations for individuals in general terms.

This higher prevalence of gastrointestinal cancer and high occurrence of female genital organ cancer in our sample are probably due to the fact that ours is a tertiary, high-complexity reference hospital in the fields of surgery, internal medicine, gynecology, obstetrics and neonatology.(17) Gastric cancer affects more men, at a 2:1 ratio, and the onset is usually after 40 years old, with its incidence peaking from 50 to 70 years old. It also affects lower socioeconomic brackets and those with lower schooling levels.(18)

In a review article about nutritional therapy in gastric cancer, researchers observed that there are two risk factors for this type of neoplasm: constitutional, or intrinsic, and environmental, or extrinsic risk. Diet is listed as the most relevant environmental risk,(19) and alcohol is also mentioned as a risk factor, as well as a state of hypochloridia or achlorhydria caused by medication, which causes pH levels that are more favorable to the formation of bacterial colonies, making Helicobacter pylori infections much easier. This promotes a chronic inflammatory process, which culminates in the onset of cancer. Oxidative stress induced by inflammation operates as a mediator for the formation or activation of cancer particles, causing DNA damage and playing an important role in that carcinogenesis process.(20)

The results obtained from oxidative stress were high, with a median value of 5.00 μM when compared with 3.31μM of healthy adult individuals.(14) When antioxidant control mechanisms are exhausted or saturated, cell redox potential moves toward oxidative stress. This, in turn, will increase the potential for damage to nucleic acids, lipids or proteins, and when that DNA damage is not repaired, it can result in mutations, establishing the role of oxidative nuclear DNA damage in cancer.(21)

As for the lipid profile of the population studied, the low HDL-c median agrees with the literature. In a systematic review, researchers observed an inverse significant association between HDL-c and the incidence of risk of cancer. This association does not depend on LDL-c, age, body mass index (BMI), diabetes and smoking.(22)Low HDL-c levels may be associated with the epidemiology of risk of developing lung cancer and with the progression of local tumors to metastatic ones.(23)

HDL-s is known for its antiatherogenic role in the body and, together with C-reactive protein, shows promising characteristics as a predictor of cardiovascular mortality.(24)

The antiatherogenic role of HDL is linked to reverse cholesterol transport (RCT), including antioxidant activities, both in vitro and in vivo, and anti-inflammatory and anti-thrombotic activities.(25,26) This activity is also related to the presence of several apolipoproteins (Apo AI, apoE, apoJ, apoA-II and apo A-IV) and the following enzymes with antioxidant properties: serum paraoxonase (PON1), platelet-activating factor acetylhydrolase (PAF-AH), lecithin-cholesterol acyltransferase (LCAT) and glutathione peroxidase (GSPx).(27) However, HDL can change in certain diseases and such modifications may alter its functions.(28)

Still comparing Groups 1 and 2, we observed greater oxidative stress in Group 1, which may be associated with poor prognosis for pancreatic and esophageal cancer, related to the invasive aggressiveness of those tumors. Despite its low incidence, pancreatic cancer has high mortality, even with an early diagnosis, just as esophageal cancer, whose 5-year survival is <10%.(29)

CONCLUSION

Most patients in the sample were male and exhibited higher oxidative stress than healthy individuals, desirable total cholesterol levels, borderline high LDL-cholesterol and low HDL-cholesterol. The latter lipoprotein was also classified as even lower among patients with gastrointestinal and accessory organ cancer. Those patients also had higher levels of oxidative stress. Therefore, their lipid profile was unfavorable, especially with respect to LDL-cholesterol and HDL-cholesterol, which seems to have contributed to a higher lipid peroxidation rate. Further studies are needed to clarify possible relations between oxidative stress and lipid profiles in gastrointestinal cancer.

REFERENCES

Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA). Coordenação de Prevenção e Vigilância. Estimativas 2014: incidência de câncer no Brasil [Internet]. Rio de Janeiro (RJ): INCA; 2014. [citado 2014 Jul 29]. Disponível em: http://www.oncoguia.org.br/oncoguia-material/estimativa-2014-incidencia-de-cancer-no-brasil/108/22/Links ]

Instituto Nacional de Câncer (INCA). O que é câncer? [Internet]. INCA. 2013 [citado 2014 Set 17]. Disponível em: http://www1.inca.gov.br/conteudo_view.asp?id=322Links ]

Gottlieb MG, Morassutti, AL, Cruz IB. Transição epidemiológica, estresse oxidativo e doenças crônicas não transmissíveis sob uma perspectiva evolutiva. Sci Med. 2011;21(2):69-80. [ Links ]

Shami NJ, Moreira EA. Licopeno como agente antioxidante. Rev Nutr. 2004; 17(2):227-36. [ Links ]

Barreiros AL, Jorge MD. Estresse oxidativo: Relação entre geração de espécies reativas e defesa do organismo. Faculdade de Farmácia. Quim Nova. 2006; 29(1):113-23. [ Links ]

Badid N, Ahmed FZ, Merzouk HB, Mokhtari N, Merzouk SA, Benhabib R, et al. Oxidant, antioxidant status, lipids and hormonal profile in overweight women with breast cancer. Pathol Oncol Res. 2009;16(2):159-67. [ Links ]

Halliwel B. Free radicals and antioxidants – quo vadis? Trends Pharmacol Sci. 2011;32(3):125-30. [ Links ]

Ehrmann-Jósko A, Siemińska J, Górnicka B, Ziarkiewicz-Wróblewska B, Ziółkowski B, Muszyński J. Impaired glucose metabolism in colorectal cancer. Scand J Gastroenterol. 2006;41(9):1079-86. [ Links ]

Farooki A, Schneider SH. Insulin resistance and cancer-related mortality. J Clin Oncol. 2007;25(12):1628-9. [ Links ]

Waitzberg DL, Nardi L, Horie LM. Desnutrição em câncer. Rev Onco & Oncologia para todas as especialidades. 2011;2(8):34-7. [ Links ]

Silva MP. Síndrome da anorexia-caquexia em portadores de câncer. Rev Bras Cancerol. 2006;52(1):59-77. [ Links ]

Cerne D, Melkic E, Trost Z, Sok M, Marc J. Lipoprotein lipase activity and gene expression in lung cancer and inadjacent non cancer lung tissue. Exp Lung Res. 2007;33(5):217-25. [ Links ]

Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978; 52:302-10. [ Links ]

Antunes MV, Lazzaretti C, Gamaro GD, Linden R. Estudo pré-analítico e de validação para determinação de malondialdeído em plasma humano por cromatografia líquida de alta eficiência, após derivatização com 2,4-dinitrofenilhidrazina. Rev Bras Cien Farm. 2008;44:279-87. [ Links ]

Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-509. [ Links ]

National Cholesterol Education Program (NCEP). National Heart, Lung, and Blood Institute. National Institutes of Health. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. NIH Publication. 2002. No. 02-5215. [ Links ]

Ceará. Governo do Estado do Ceará. Secretaria de Saúde. Hospital Dr. Geral César Cals. 2012. O Hospital [Internet]. [cited 2012 Out 31] Available from: http://www.hgcc.ce.gov.br/index.php/o-hospital. [ Links ]

Arregi MM, Ferrer DP, Assis EC, Paiva FD, Sobral LB, Andre NF, et al. Perfil clinico-epidemiológico das neoplasias de estomago atendidas no Hospital do Câncer do Instituto do Câncer do Ceará, no período de 2000-2004. Rev Bras Cancerol. 2009;55(2):121-8. [ Links ]

Mendonça RX, Gagliardo LC, Ribeiro RL. Câncer gástrico: a importância da terapia nutricional. Saúde Amb Rev. 2008;3(2):7-19. [ Links ]

Ladeira MS, Salvadori DM, Rodrigues MA. Biopatologia do Helicobacter pylori. J Bras Patol Med Lab. 2003;39(4):335-42. [ Links ]

Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239-67. Review. [ Links ]

Jafri H, Alsheikh AA, Karas RH. Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. J Am Coll Cardiol. 2010;55(25):2846-54. [ Links ]

McGrowder D, Riley C, Morrison EY, Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol. 2011;2011:496925. [ Links ]

Laks R, Araújo LM, Almada Filho CM, Cendoroglo MS. The importance of HDL-C and CRP in cardiovascular risk evaluation in longevous elderly individuals. Einstein. 2011;9(3):397-403. [ Links ]

Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111(12):1543-50. [ Links ]

Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58(3):342-74. [ Links ]

Pan B, Ren H, Lv X, Zhao Y, Yu B, He Y, et al. Hypochlorite-induced oxidative stress elevates the capability of HDL in promoting breast cancer metastasis. J Transl Med. 2012;10:65. [ Links ]

Pan B, Ren H, He Y, Lv X, Ma Y, Li J, et al. HDL of patients with type 2 diabetes mellitus elevates the capability of promoting breast cancer metastasis. Clin Cancer Res. 2012;18(5):1246-56. [ Links ]

Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20(2):197-209. [ Links ]

Received: March 21, 2014; Accepted: August 29, 2014

Corresponding author: Fernanda Maria Machado Maia − Universidade Estadual do Ceará, Avenida Dr. Silas Munguba, 1.700 − Itaperi – Zip code: 60714-903 – Fortaleza, CE, Brazil − Phone: (55 85) 3101-9821 E-mail:fernandammm3@yahoo.com.br

Conflict of interest: none.

Creative Commons License This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.